Home > Boards > US OTC > Biotechs > Inspyr Therapeutics Inc. (NSPX)

Just want to clear something up and confirm

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Goodmooring Member Profile
Followed By 2
Posts 294
Boards Moderated 1
Alias Born 01/02/18
160x600 placeholder
Goodmooring   Friday, 10/04/19 08:04:13 AM
Re: flaflyersfan post# 9142
Post # of 9325 
Just want to clear something up and confirm your view.

Information is key! Anyone can ask me a question and will get an answer with verifiable information. I like to help people.

You only care about numbers and have no interest in this company's actual operations or future.

I continue to post verifiable Published DD in regards to the company's past/present/future.

You continue to say the same thing, that this company has debt and needs to pay it off. You post no break down of your numbers. You change your numbers every other week. You say if someone wants to find the numbers they need to do the DD themselves. You post nothing to backup your unfounded numbers. One post you said the company was in 8 million debt then 11 million debt then 60 million debt.

Every company has debt and needs to come up with a plan to pay it off.
They are on that higher end of debt as stated in their Sept. 13th, 2019 filings: "We have incurred losses since inception and have an accumulated deficit of $61 million as of June 30, 2019".
Since their inception... BioTech company with ONLY 61 million in debt since 2003(Inception), Sounds like a BioTech company for over 16 years that does not waste money to me.. 61 million is high for 5 years but extremely low for 16 years


NSPX has come up with a plan, followed through, with their best available impact on shareholders. No one likes an RS. That goes without saying.

$NSPX has no sales. I agree
$NSPX is a BioTech company. What BioTech company does not have literally $hundreds of millions of dollars in Debt.
$NSPX has a very important drug "Mipsagargin" that requires further investigation. As stated in their latest Published Clinical Phase II Trials update on June 17th, 2019.
$NSPX cannot move forward without a commercially synthesized supply of Thapsigargin. This is continually being pushed by Phyton BioTech "Global Leaders in Plant Cell Fermentation".
$NSPX played it right over the last 2 years. Minimize new debt. Wait for Thapsigargin to be commercially synthesized.

Unfortunately they need to pay for debts which are coming due. Thus the need for the RS to raise money.
To only look at the numbers of this Company is a great disadvantage and dishonest attempt to drive a Share Price down.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist